Data updated: Mar 10, 2026
LUMIFY
BRIMONIDINE TARTRATE
Approved 2017-12-22
1
Indication
--
Phase 3 Trials
8
Years on Market
Details
- Status
- Over-the-counter
- First Approved
- 2017-12-22
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
LUMIFY Approval History
Loading approval history...
What LUMIFY Treats
1 FDA approvalsOriginally approved for its first indication in 2017 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LUMIFY FDA Label Details
ProLUMIFY Patents & Exclusivity
Latest Patent: Jul 2030
Patents (4 active)
US8293742
Expires Jul 14, 2030
US9259425
Expires Jul 14, 2030
US11596600
Expires Jul 27, 2029
US11833245
Expires Jul 27, 2029
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.